THERAPY DOSSIER · th-e6d8de67b2c9

Soluble CD73 (5'-ectonucleotidase); macrophage depletion used as a second intervention

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31364375 ↗2019Reported benefit

Perivascular CD73 cells attenuate inflammation and interstitial fibrosis in the kidney microenvironment.

MouseIschaemia-reperfusionRenal

Model: Unilateral kidney ischaemia-reperfusion injury, or folic acid nephropathy induced by folic acid 250 mg/kg, evaluated 14 days after injury

Deletion of CD73 from kidney perivascular cells increased collagen deposition, proinflammatory and macrophage marker expression and PDGFR-beta immunoreactivity at 14 days after unilateral ischaemia-reperfusion injury or folic acid treatment. Kidney dysfunction and fibrosis were rescued by administr…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.45. Machine-extracted fields require source verification.

Loading the evidence…